|
|
|
|
||
Re: Sangamo sees the future in LNPQuote from RBC, October 2016 ABUS has key IP in the LNP space that is important to gene editing companies; it is possible that ABUS is able to allow licenses to this IP for cash upfront payments and/or milestones, which is also not well known on the Street and additional upside. |
return to message board, top of board |